Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer

被引：0

作者：

Takahashi, Toshiaki ^{[1
]}

Yamamoto, Nobuyuki ^{[1
]}

Nukiwa, Toshihiro ^{[2
]}

Mori, Kiyoshi ^{[3
]}

Tsuboi, Masahiro ^{[4
]}

Horai, Takeshi ^{[5
]}

Masuda, Noriyuki ^{[6
]}

Eguchi, Kenji ^{[7
]}

Mitsudomi, Tetsuya ^{[8
]}

Yokota, Soichiro ^{[9
]}

Segawa, Yoshihiko ^{[10
]}

Ichinose, Yukito ^{[11
]}

Fukuoka, Masahiro ^{[12
]}

Saijo, Nagahiro ^{[13
]}

机构：

[1] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[2] Tohoku Univ, Inst Dev Aging & Canc, Dept Resp Oncol & Mol Med, Sendai, Miyagi 980, Japan

[3] Tochigi Canc Ctr, Dept Med Oncol, Div Thorac Oncol, Mibu, Tochigi, Japan

[4] Tokyo Med Univ, Dept Surg, Tokyo, Japan

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Thorac Ctr, Tokyo, Japan

[6] Kitasato Univ, Grad Sch Med Sci, Dept Resp Med, Kanagawa, Japan

[7] Tokai Univ, Sch Med, Dept Med Oncol, Kanagawa 2591100, Japan

[8] Aichi Canc Ctr Hosp, Dept Thorac Surg, Aichi, Japan

[9] Toneyama Natl Hosp, Natl Hosp Org, Dept Resp Med, Osaka, Japan

[10] Shikoku Canc Ctr, Natl Hosp Org, Dept Med & Thorac Oncol, Shikoku, Ehime, Japan

[11] Kyushu Natl Canc Ctr, Natl Hosp Org, Dept Thorac Oncol, Fukuoka, Japan

[12] Kinki Univ, Sch Med, Dept Med Oncol, Osaka 589, Japan

[13] Natl Canc Ctr Hosp E, Chiba, Japan

来源：

ANTICANCER RESEARCH | 2010年 / 30卷 / 02期

关键词：

Non-small cell lung cancer; erlotinib; Tarceva; EGFR-TKIs; EGFR mutation; phase II; TYROSINE-KINASE INHIBITOR; SOLID TUMORS; PHARMACOKINETICS; EFFICACY; BENEFIT; GEFITINIB; SURVIVAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent advanced non-small cell lung cancer (NSCLC). Patients and Methods: This was a multicentre, open-label phase 11 study of erlotinib (150 mg/day) in patients with stage IIIB or IV NSCLC. The primary endpoint was the objective tumour response rate. Results: Of the 46 patients, 13 were assessed to have a partial response and 9 had stable disease. The median duration of response was 449 days and time to progression vas 75 days. Median overall survival (OS) was 13.5 months and the 1-year survival rate was 56.5%. The most common adverse events were dermal or gastrointestinal, and were mainly grade 2 or less. An exploratory analysis suggested a link between rash severity and OS. Conclusion: Erlotinib has promising antitumour activity and is generally well tolerated in Japanese patients with previously treated NSCLC.

引用

页码：557 / 563

页数：7

共 50 条

[21] Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer
Kaburagi, Takayuki
Satoh, Hiroaki
Hayashihara, Kenji
Endo, Takeshi
Hizawa, Nobuyuki
Kurishima, Koichi
Nishimura, Yoshihiro
Hashimoto, Toshio
Nakamura, Hiroyuki
Kishi, Koji
Inagaki, Masaharu
Nawa, Takeshi
Ichimura, Hideo
Ishikawa, Hiroichi
Kagohashi, Katsunori
Fukuoka, Toshihiko
Shinohara, Yoko
Kamiyama, Koichi
Sato, Yukio
Sakai, Mitsuaki
Matsumura, Takeshi
Uchiumi, Keiko
Furukawa, Kinya
ONCOLOGY LETTERS, 2013, 5 (02) : 435 - 439
[22] Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations
Inoue, Yusuke
Inui, Naoki
Asada, Kazuhiro
Karayama, Masato
Matsuda, Hiroyuki
Yokomura, Koshi
Koshimizu, Naoki
Imokawa, Shiro
Yamada, Takashi
Shirai, Toshihiro
Kasamatsu, Norio
Suda, Takafumi
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (01) : 155 - 161
[23] The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
Grossi, Francesco
Rijavec, Erika
Dal Bello, Maria Giovanna
Defferrari, Carlotta
Brianti, Annalisa
Barletta, Giulia
Genova, Carlo
Murolo, Carmelina
Cosso, Maurizio
Fontanini, Gabriella
Boldrini, Laura
Truini, Mauro
Pronzato, Paolo
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1407 - 1412
[24] Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
Passaro, Antonio
Alesini, Daniele
Pochesci, Alessia
Cortesi, Enrico
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (05) : 646 - 650
[25] Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer
O'Mahar, Shannon E.
Campbell, Toby C.
Tien Hoang
Seo, Songwon
Kim, KyungMann
Larson, Martha M.
Marcotte, Sarah M.
LoConte, Noelle K.
Traynor, Anne M.
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (05) : 951 - 953
[26] PHASE II TRIAL OF ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER
Okano, Yoshio
Shinohara, Tsutomu
Machida, Hisanori
Hatakeyama, Nobuo
Takeuchi, Eiji
Doi, Hiroyuki
Kubota, Tetsuya
Yokoyama, Akihito
Ogushi, Fumitaka
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1175 - S1176
[27] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
Yang, J. J.
Zhou, Q.
Yan, H. H.
Zhang, X. C.
Chen, H. J.
Tu, H. Y.
Wang, Z.
Xu, C. R.
Su, J.
Wang, B. C.
Jiang, B. Y.
Bai, X. Y.
Zhong, W. Z.
Yang, X. N.
Wu, Y. L.
BRITISH JOURNAL OF CANCER, 2017, 116 (05) : 568 - 574
[28] ERLOTINIB FOR CHINESE ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
Wang, H-P
Li, Z.
Wang, M-Z
Yi, X.
RESPIROLOGY, 2011, 16 : 172 - 172
[29] Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non-Small-Cell Lung Cancer (NSCLC) An Interim Analysis of 3488 Patients (POLARSTAR)
Nakagawa, Kazuhiko
Kudoh, Shoji
Ohe, Yuichiro
Johkoh, Takeshi
Ando, Masahiko
Yamazaki, Naoya
Seki, Akihiro
Takemoto, Shinya
Fukuoka, Masahiro
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (08) : 1296 - 1303
[30] A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer
Fujiwara, Atsushi
Yoshida, Masamichi
Fujimoto, Hajime
Nakahara, Hiroki
Ito, Kentaro
Nishihama, Kota
Yasuma, Taro
Hataji, Osamu
Taguchi, Osamu
D'Alessandro-Gabazza, Corina N.
Gabazza, Esteban C.
Kobayashi, Tetsu
ONCOLOGY RESEARCH, 2018, 26 (07) : 1031 - 1036

← 1 2 3 4 5 →